Roadmap to implementation of a fully automated blood‐based biomarker test to facilitate diagnosis and treatment in early Alzheimer’s disease

Routine implementation of a fully automated blood based biomarker (BBBM) will expand access to diagnosis and initiation of disease modifying therapies (DMTs) in Alzheimer’s disease (AD). This analysis explores current obstacles in the AD diagnostic pathway, the unmet need for a BBBM test to facilitate referral decisions, and barriers to BBBM testing.